Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 2
R&D Momentum
64/100
Pipeline Velocity
30/100
Trial Completion Rate
N/A
Pipeline Concentration
50/100
Pipeline Freshness
37/100
Strategic Signals
Activity
Last 14 days
Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease
Translocator Protein PET/CT in Various TSPO-Related Disease
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Clinical Study of [18F]FT8 PET/CT in Evaluating Amyloidosis
FAPI PET/CT in Various FAP-Related Disease Patients
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
Tau PET/CT in Various Tau-Related Disease Patients
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)